

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 December 2023 (21.12.2023)



(10) International Publication Number
WO 2023/244764 A1

(51) International Patent Classification:

A61K 31/501 (2006.01) *A61K 31/4545* (2006.01)
A61K 31/397 (2006.01) *A61K 47/55* (2017.01)
A61K 31/45 (2006.01)

(21) International Application Number:

PCT/US2023/025484

(22) International Filing Date:

15 June 2023 (15.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/352,444 15 June 2022 (15.06.2022) US

(71) Applicant: **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(72) Inventors: **NASVESCHUK, Christopher, G.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **LAZARSKI, Kiel**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **LIANG, Yanke**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HUANG, Hongwei**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **GOOD, Andrew Charles**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HIRD, Alexander W.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **YIN, Ning**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HENDERSON, James A.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **PARK, Eunice Sun**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **ERON, Scott Joseph**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **DEIBLER, Richard Wendel**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **JACKSON, Katrina L.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(74) Agent: **BELLOWS, Brent R.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2



(I)

(57) Abstract: The invention provides a bifunctional compound of formula (I) comprising a Targeting Ligand that binds to SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 2 (SMARCA2) conjugated to a Degron that is capable of binding to E3 Ubiquitin Ligase, or a pharmaceutically acceptable salt thereof, wherein R1, Cy1, Cy2, Cy3, Cy4, Z1, Z2 and the degron are as described herein. Further disclosed a method of treating a patient having a SMARCA2-mediated disorder, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutical composition.

WO 2023/244764 A1